Waoo Takes TV Authentication and Analytics to the Cloud with Verimatrix
15.4.2020 18:45:00 EEST | Business Wire | Press release
Verimatrix, (Euronext Paris: VMX), formerly known as Inside Secure, a global provider of innovative, customer-friendly cybersecurity solutions that protect video content, endpoint devices, software and applications, today announced that Waoo, Denmark's leading provider of internet, TV, streaming and telephony via the fiber network, has selected the Verimatrix Video Content Authority System (VCAS™) for IPTV, Verimatrix Multi-DRM and Verimatrix Analytics – all as software-as-a-service (SaaS) solutions. Lower capital investment and faster time-to-market through cloud-based services provide Waoo a competitive advantage in the Danish market.
“Unifying our security and analytics platforms with a single partner gives us better economies of scale along with streamlined management of the solutions – via the power of the cloud,” said Ole Ørndrup, CTO of Waoo. “We believe in the Verimatrix product roadmap to help future proof our networks and deliver the best experience for our subscribers.”
The cloud-based VCAS content and revenue security platform provides two-way protection for premium content on Waoo’s IPTV network, while Verimatrix Multi-DRM reduces complexity which allow the operator to retain full control of its service offerings and subscriber relationships. Cloud-native Verimatrix Analytics unifies data across Waoo’s IPTV and OTT networks and end devices to help optimize multi-network video service delivery and the subscriber viewing experience, which ultimately improves user engagement and increases revenue.
“We are pleased to extend our relationship with Waoo where we are helping the company take advantage of benefits of the SaaS model to streamline complexity, analytics and security,” said Asaf Ashkenazi, COO of Verimatrix. “With our flexible deployment options and strong partner ecosystem, Waoo is better able to offer a range of advanced services that meet their customers’ growing needs helping to maximize service revenue and ROI.”
The Verimatrix solutions are integrated with the Nordija fokusOn middleware solution and will be extended to set-top boxes and in-home WiFi equipment to maximize the business impact of the multi-network, multi-screen video intelligence platform.
Visit the Verimatrix website to learn more about VCAS, Verimatrix Multi-DRM and Verimatrix Analytics solutions or attend next week’s Verimatrix Virtual Summit. The online forum will present the news planned to be unveiled at NAB, in addition to providing participants with an in-depth product review and Q&A session immediately following. Visit our website to sign up to attend the kickoff webinar and schedule a private, 1-on-1 meeting: www.verimatrix.com/events/verimatrix-virtual-summit.
About Waoo
Waoo is Denmark's leading provider of entertainment and communication over fiber. Waoo's products on the internet, TV, streaming and telephony are provided by the local fiber network company, which also provides consulting, installation, support and customer service. For 8 consecutive years Waoo has been elected as Denmark’s best internet provider. Waoo Fiber has a speed guarantee, high stability and lots of capacity, so its products make it possible to realize the full potential of the internet. For more information visit www.waoo.dk
About Verimatrix
Verimatrix (Euronext Paris: VMX), formerly known as Inside Secure, is a global provider of innovative, customer-friendly cybersecurity solutions that protect content, devices, software and applications across multiple markets. Many of the world’s largest service providers and leading innovators trust Verimatrix to protect systems that people depend on every day. With more than 20 years of experience and the top minds in the industry, the company is uniquely positioned to understand and proactively anticipate security and business challenges for customers. Verimatrix partners to provide innovative, customer-friendly solutions that are cost-effective, easy to deploy and supported with responsive customer service teams based worldwide. To learn more, visit www.verimatrix.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200415005049/en/
Contact information
Investor and media contacts
Investor Relations
Richard Vacher Detournière
General Manager & Chief Financial Officer
+33 (0)4 42 905 905
finance@verimatrix.com
Contact Media
Kelly Foster
+1 619 224 1261
kfoster@verimatrix.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom